Abstract
Mesenchymal stromal cells (MSCs) show great promise in ameliorating kidney disease. These multipotent fibroblast‐like stromal cells can migrate to damaged kidneys, where they selectively home to inflammatory cues and alter the course of injury. MSCs can elicit endogenous repair through paracrine and/or endocrine mechanisms that modulate the immune response, ultimately allowing for cellular replacement. This chapter reviews new approaches using MSCs as delivery vehicles for secreted proteins and methods for improving efficacy. Despite uncertainty over mechanisms mediating protection, MSCs are currently in clinical trials for a range of acute and chronic diseases, including kidney disorders. The chapter discusses the challenges in applying MSCs in a setting of chronic kidney disease (CKD). It highlights the potential of a combined therapeutic approach using MSCs and an anti‐fibrotic, relaxin, to aid in MSC viability and the promotion of endogenous repair, cellular replacement, and attenuation of fibrosis.
| Original language | English |
|---|---|
| Title of host publication | The Biology and Therapeutic Application of Mesenchymal Cells |
| Place of Publication | Hoboken, New Jersey |
| Publisher | John Wiley & Sons |
| Chapter | 51 |
| Pages | 754-769 |
| Number of pages | 16 |
| ISBN (Electronic) | 9781118907375, 9781118907290 |
| ISBN (Print) | 9781118907511 |
| Publication status | Published - 2017 |